LETTER TO THE EDITOR |
To the Editor.—
Sicherer et al are to be commended for a fine, comprehensive article on the role of self-injectable epinephrine in the management of anaphylaxis.1 However, there is one misstatement that I feel should be corrected. In describing when self-injectable epinephrine should be prescribed, the authors stated that it should be prescribed to a child who has experienced generalized acute urticaria after an insect sting, "because the risk of a more severe reaction from a future sting is approximately 10%." However, the reference they give (a practice parameter update2) actually states that "patients 16 years of age and younger who have experienced cutaneous systemic reactions without other allergic manifestations have approximately a 10% chance of having a systemic reaction if re-stung. If a systemic reaction does occur, it is likely to be limited to the skin."
This is clarified even further in the original reference on which the above-mentioned statement was based,3 which stated that "196 stings in 86 untreated children resulted in 18 systemic reactions... . Sixteen of these 18 reactions were judged to be milder than the patient's reaction to the first sting, 2 were similar in severity, and none were more severe." Therefore, although it is certainly not unreasonable to prescribe self-injectable epinephrine for children with cutaneous-only reactions to insect stings, we can also be quite reassuring to patients and caregivers that the chances of a more severe reaction are, in fact, very small.
REFERENCES
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||